ENTERO Entero Healthcare Solutions Q2 FY25 results (Jul–Sep 2024) and concall
Entero Healthcare Solutions delivered a strong Q2 FY25, with consolidated revenue growing 31% YoY to ₹1,301 crores, driven by both organic expansion (15%) and strategic acquisitions. Profitability saw significant improvement, with EBITDA increasing 49% to ₹42 crores and EBITDA margin expanding by 40 basis points to 3.3%. The company remains on track to achieve its FY25 revenue growth and margin targets, supported by ongoing procurement efficiencies, product mix optimization, and a robust acquisition pipeline.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 |
|---|---|
| Revenue | 1,301 |
| EBITDA | 42 |
| Net profit | 26 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
